Thalidomide Synergistically Regulates Cell Cycle and Endoplasmic Reticulum Stress to Alleviate RPE Oxidative Damage Through the E2F2 ‐ FBXO5 Pathway
The FASEB Journal · 2026
DOI: 10.1096/fj.202502444r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2026. Verfasst von Jingya Zhu und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology and …. Hauptthemen laut MEDLINE: Endoplasmic Reticulum Stress, Oxidative Stress, Thalidomide, Retinal Pigment Epithelium. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: GDSTC | Natural Science Foundation of Guangdong Province (), Scientific and Technological Planning Project of Guangzhou City (), State Key Laboratory of Ophthalmology (SKLO).
Abstract (Originalsprache)
Thalidomide, a glutamate derivative with teratogenicity, possesses anti‐inflammatory, immunomodulatory, and anti‐angiogenic properties that enable its use in treating refractory diseases unresponsive to conventional therapies. Dry age‐related macular degeneration (AMD), characterized by retinal pigment epithelium (RPE) degeneration and lacking effective therapies, represents a significant unmet medical need. Our findings demonstrated that thalidomide significantly restores mitochondrial function, alleviates G2/M phase cell cycle arrest, and suppresses sustained endoplasmic reticulum (ER) stress in oxidatively injured RPE cells. Mechanistically, these effects are coordinated through E2F2 activation, which subsequently regulates FBXO5 expression. Moreover, thalidomide was able to ameliorate oxidative stress‐induced retinal structural disorders and RPE degeneration, and improve visual function in mice. In summary, this study elucidates that thalidomide synergistically regulates cell cycle progression and endoplasmic reticulum homeostasis through the E2F2‐FBXO5 signaling pathway, providing a new drug candidate and therapeutic target for the prevention and treatment of dry AMD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, Guangdong, China.
- Department of Pathology, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.
- Biobank of Eye, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, Guangdong, China.
ORCID-Profile: Jingya Zhu, Huangxuan Shen
Förderung
- GDSTC | Natural Science Foundation of Guangdong Province ()
- Scientific and Technological Planning Project of Guangzhou City ()
- State Key Laboratory of Ophthalmology (SKLO)
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Zhu, J., Yu, X., Wen, C., Zhang, Y., Kuang, X., Sun, N., Tang, S., Xiao, B., Xiao, S., Wang, X., Wu, K., Zhang, Q., & Shen, H. (2026). Thalidomide Synergistically Regulates Cell Cycle and Endoplasmic Reticulum Stress to Alleviate RPE Oxidative Damage Through the E2F2 ‐ FBXO5 Pathway. The FASEB Journal. https://doi.org/10.1096/fj.202502444r
Vancouver
Zhu J, Yu X, Wen C, Zhang Y, Kuang X, Sun N, et al. Thalidomide Synergistically Regulates Cell Cycle and Endoplasmic Reticulum Stress to Alleviate RPE Oxidative Damage Through the E2F2 ‐ FBXO5 Pathway. The FASEB Journal. 2026. doi:10.1096/fj.202502444r
BibTeX
@article{Zhu2026,
author = {Zhu, Jingya and Yu, Xinyue and Wen, Chaojuan and Zhang, Youao and Kuang, Xielan and Sun, Nan and Tang, Shiyu and Xiao, Bing and Xiao, Sainan and Wang, Xun and Wu, Kaili and Zhang, Qingjiong and Shen, Huangxuan},
title = {Thalidomide Synergistically Regulates Cell Cycle and Endoplasmic Reticulum Stress to Alleviate RPE Oxidative Damage Through the E2F2 ‐ FBXO5 Pathway},
journal = {The FASEB Journal},
year = {2026},
doi = {10.1096/fj.202502444r}
}
EUVIMED